A carregar...

Enzalutamide for patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. DATA SOURCES: Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Ramadan, Wijdan H, Kabbara, Wissam K, Al Basiouni Al Masri, Hiba S
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4407758/
https://ncbi.nlm.nih.gov/pubmed/25945058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S80488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!